Therapeutic strategies for social anxiety disorder: where are we now?
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Introduction: Classical well-established treatments of social anxiety disorder (SAD) are now complemented by more recent therapeutic strategies. This review aims to summarize available therapies for SAD and discuss recent evidence-based findings on the management of this disorder.Areas covered: Recent guidelines recommend psychotherapy, particularly cognitive-behavioral therapy (CBT), and pharmacotherapy, as first-line treatments of patients with SAD, without a clear superiority of one option over the other. CBT includes classical approaches such as in vivo exposure to social situations and cognitive therapy, but new modalities and techniques have been recently developed: third-wave approaches, internet-delivered therapy, virtual reality exposure, and cognitive bias modification. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors have been also extensively studied and shown to be effective in SAD. Two alternative strategies have been developed to treat SAD with disappointing results: cognitive bias modification, and pharmacological augmentation of psychotherapy using D-cycloserine during exposure sessions.Expert opinion: Personalized treatments for SAD patients are now available. Innovative strategies such as online psychotherapy and virtual reality exposure are useful alternatives to CBT and SSRIs. Future developments and optimization of attention bias modification and of pharmacological augmentation of psychotherapy can be promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · cited 1×
“general population, with an estimated lifetime prevalence ranging from 2% to 13%, depending on the diagnostic threshold [3,4].”
BackgroundMerikangas, K. R., He, J.-P., Burstein, M., Swendsen, J., Avenevoli, S., Case, B., Georgiades, K., Heaton, L., Swanson, S., & Olfson, M. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.10.006 · Cited by 1,579
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 9×
“600 mg/day for pregabalin, and with effect sizes lower than those obtained in studies of SSRIs [18,89].”
BackgroundInfluentialSocial fears and social phobia in the USA: results from the National Comorbidity survey replication
Ruscio, A. M., Brown, T. A., Chiu, W. T., Sareen, J., Stein, M. B., & Kessler, R. C. (2008) · Psychological Medicine · doi:10.1017/s0033291707001699 · Cited by 835 · cited 1×
“Even if the barriers to diagnosis and treatment are still an issue in most countries for this oftenneglected disorder [11,13], classical care can improve outcome”
BackgroundHayes, S. C. (2016) · Behavior Therapy · doi:10.1016/j.beth.2016.11.006 · Cited by 785 · cited 1×
“Third wave interventions are based on psychological flexibility processes, values and acceptance [29].”
BackgroundBergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 1×
“For example, when given as a high single dose, cannabidiol may have anxiolytic effects that are both objective and subjective such as a significant decrease in speech performance difficulties [95,96].”
BackgroundMayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680 · cited 3×
“Meta-analyses and guidelines tend to propose psychotherapy as the first line treatment, essentially based on a long-term perspective [15,19,26].”
BackgroundClark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561 · cited 1×
“In two randomized studies, no significant difference was found between fluoxetine [70] or sertraline [71] and CBT, but two others found cognitive therapy to be superior to fluoxetine [72] and paroxetine [73].”
Background
Research works printed but not linked: 64
- 10.1176/appi.books.9780890425596 · DOI · Paper page
- 10.1016/j.euroneuro.2005.04.002 · DOI · Paper page
- 10.1002/(SICI)1520-6394(2000)11:3<87::AID-DA1>3.0.CO;2-9 · DOI
- 10.1016/j.brat.2016.06.007 · DOI · Paper page
- 10.1016/j.jad.2010.07.031 · DOI
- 10.2147/NDT.S23317 · DOI · Paper page
- 10.1136/bmj.f2541 · DOI · Paper page
- 10.1002/da.20771 · DOI
- 10.1016/j.brat.2005.08.010 · DOI
- 10.1016/j.encep.2012.01.011 · DOI
- 10.1007/s11920-016-0667-4 · DOI
- 10.1002/jclp.21842 · DOI · Paper page
- 10.1136/bmjopen-2017-017053 · DOI
- 10.1037/pst0000147 · DOI · Paper page
- 10.3233/THC-151014 · DOI · Paper page
- 10.2196/13869 · DOI
- 10.1007/s11920-014-0545-x · DOI
- 10.1016/j.beth.2018.04.002 · DOI
- 10.1037/a0016685 · DOI · Paper page
- 10.1016/j.jbtep.2017.10.006 · DOI
- 10.1016/j.brat.2012.02.015 · DOI · Paper page
- 10.1002/da.22634 · DOI
- 10.1016/j.janxdis.2011.08.001 · DOI
- 10.1016/j.psychres.2016.04.019 · DOI
- Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev. 2017;10:CD001206.
- 10.1586/14737175.8.2.235 · DOI · Paper page
- 10.1097/01.jcp.0000106222.36344.96 · DOI · Paper page
- 10.1192/bjp.179.1.23 · DOI · Paper page
- 10.1159/000447013 · DOI · Paper page
- 10.1007/s00213-004-1957-9 · DOI
- 10.1001/jama.280.8.708 · DOI · Paper page
- 10.1111/j.1600-0447.1999.tb10845.x · DOI · Paper page
- 10.1192/bjp.175.2.120 · DOI · Paper page
- 10.4088/JCP.v63n0113 · DOI · Paper page
- 10.1016/j.janxdis.2007.03.001 · DOI
- 10.1016/j.euroneuro.2009.10.005 · DOI
- 10.1176/ajp.156.5.756 · DOI · Paper page
- 10.1017/S1461145706006602 · DOI · Paper page
- 10.1176/ajp.152.9.1368 · DOI · Paper page
- 10.4088/JCP.v64n0708 · DOI · Paper page
- 10.1097/00004714-200206000-00005 · DOI · Paper page
- 10.1016/j.biopsych.2005.03.029 · DOI · Paper page
- 10.1097/01.jcp.0000138764.31106.60 · DOI · Paper page
- 10.1001/archpsyc.62.2.190 · DOI · Paper page
- 10.1097/YIC.0b013e32834519bd · DOI · Paper page
- 10.2174/15748847113089990059 · doi:10.2174/15748847113089990059
- 10.1176/appi.ajp.2014.14010048 · DOI
- 10.1002/mpr.1719 · DOI
- 10.1080/15622970802465807 · DOI · Paper page
- 10.1017/S2045796018000239 · DOI
- 10.1017/S1461145711001489 · DOI · Paper page
- 10.1007/s00127-003-0720-6 · DOI
- 10.1007/s00127-008-0309-1 · DOI
- 10.1016/S0887-6185(00)00026-8 · DOI
- 10.1111/eip.12372 · DOI · Paper page
- 10.1177/2045125317714193 · DOI
- 10.1016/S0193-953X(05)70266-5 · DOI
- 10.1016/j.chc.2011.08.011 · DOI · Paper page
- 10.1002/da.20410 · DOI · Paper page
- 10.1186/1753-2000-5-5 · DOI · Paper page
- 10.1016/j.janxdis.2005.01.003 · DOI
- 10.1586/14737175.2013.853446 · DOI
- 10.1016/j.brat.2009.09.012 · DOI
- 10.1007/s11920-014-0531-3 · DOI · Paper page
Cited by
Virtual reality therapy in social anxiety disorder
Emmelkamp, P. M. G., Meyerbröker, K., & Morina, N. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-01156-1 · Cited by 150
“As noted by Pelissolo et al. [55], the effect size for attention bias modification reported is smaller than standard placebo effect sizes in RCTs examining the treatment of SAD.”
ResultMaximizing the impact of virtual reality exposure therapy for anxiety disorders
Anderson, P. L., & Molloy, A. (2020) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2020.10.001 · Cited by 38
Wechsler, T. F., Pfaller, M., Eickels, R. E. V., Schulz, L. H., & Mühlberger, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.751272 · Cited by 21
“Reviews and meta-analyses (39, 40, 42, 43) as well as recent studies on VR-based trainings (44, 45) provide contradictory results concerning the effects on Social Anxiety.”
ResultStefaniak, I., Hanusz, K., Mierzejewski, P., Bieńkowski, P., Parnowski, T., & Murawiec, S. (2022) · Brain Sciences · doi:10.3390/brainsci12091236 · Cited by 12
“Pellisolo’s study shows that VRET can be seen as an alternative to CBT and SSRI therapy [48].”
BackgroundAndreoli, G., Kasch, C., Lindsay, C. E., & Hofmann, S. G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2604303 · Cited by 2
Metadata
- Authors
- Pelissolo, A., Abou Kassm, S., & Delhay, L.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2019-09-13
- Volume
- 19
- Issue
- 12
- Pages
- 1179-1189
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2973211619
- Cited by
- 57
- References
- 62
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic strategies for social anxiety disorder: where are we now? https://app.cochat.ai/papers/10.1080/14737175.2019.1666713
- The paper
- Pelissolo, A., Abou Kassm, S., & Delhay, L. (2019). Therapeutic strategies for social anxiety disorder: where are we now? Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2019.1666713
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.